Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects-Reference-Cited by-同舟云学术

Discovery of Novel HDAC3 Inhibitors with PD-L1 Downregulating/Degrading and Antitumor Immune Effects

Published:2024-07-20 Issue:15 Volume:67 Page:13067-13088
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Sun Zhiqiang¹,Xu Chenglong¹,Cheng Jinmei²,Yang Zichao¹,Liu Ting¹,Deng Bulian¹,Zhang Xuewen¹,Peng Xiaopeng³,Chen Jianjun¹^ORCID

Affiliation:

1. School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China

2. Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China

3. Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Jiangxi Province Key Laboratory of Biomaterials and Biofabrication for Tissue Engineering, School of Pharmacy, Gannan Medical University, Ganzhou 314000, China

Funder

Bureau of Science and Technology of Ganzhou Municipality

Southern Medical University

National Natural Science Foundation of China

Natural Science Foundation of Jiangxi Province

Thousand Young Talents Program of China

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c01062

Reference55 articles.

1. Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

2. Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

3. Cancer Epigenetics: From Mechanism to Therapy

4. Inhibition of DNA methyltransferases, histone deacetylases and lysine-specific demethylase-1 suppresses the tumorigenicity of the ovarian cancer ascites cell line SKOV3

5. HDAC inhibitor LMK‑235 promotes the odontoblast differentiation of dental pulp cells